泛昔洛韦分别联合干扰素γ、胸腺肽抗乙肝病毒疗效的临床观察  

作　　者：龚守军[1] 贾蕊菡 张夏华[1] 

机构地区：[1]中国·武警上海总队医院201103

出　　处：《美国中华健康卫生杂志》2003年第2期54-55,共2页

摘　　要：Objective To observe the efficacy of anti - HBV DNA medicine and different combina-tion. Methods 170 ASC CHB patients were categorized into two groups( group Ⅰ, hays 65 patients, they were randomised to receive Famcilovir combine with Interferon- γ; group Ⅱ , hays 105 patients they were randomised to receive Famcilovir combine with Thymopentin), the controls treat by Interferon - a2b. Re-stilt 53.3 % of the group Ⅰ and 38.3 % of the group Ⅱ had undetectable serum HBV DNA, compared with 28.6% in the control group: the people diminition 10^2 coples/ml,38.8% of whom are in the group Ⅰ ,49.5% whom are in the group Ⅱ ,compared with 28.6% in control group(P < 0.025) ;After treat-ment, they also go down more obviously in HBeAg HbsAg and the group Ⅰ is better than the group Ⅱ .Conclusion Conbination of two different medicine is a useful method, and it may indicate that much time is neccssary to receive anti- HBV DNA patients, especially to theose accept immune treatment.

关 键 词：乙型肝炎 药物治疗 泛昔洛韦 干扰素Γ 胸腺肽 

分 类 号：R512.62[医药卫生—内科学] R978.7[医药卫生—临床医学]